Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Sales (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Return on Sales for 16 consecutive years, with 0.86% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales rose 15.0% year-over-year to 0.86%, compared with a TTM value of 0.79% through Sep 2025, up 7.0%, and an annual FY2024 reading of 1.05%, down 61.0% over the prior year.
  • Return on Sales was 0.86% for Q3 2025 at China Pharma Holdings, down from 0.52% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.24% in Q1 2023 and bottomed at 1.55% in Q2 2024.
  • Average Return on Sales over 5 years is 0.61%, with a median of 0.54% recorded in 2023.
  • The sharpest move saw Return on Sales crashed -101bps in 2024, then skyrocketed 104bps in 2025.
  • Year by year, Return on Sales stood at 0.34% in 2021, then decreased by -28bps to 0.43% in 2022, then plummeted by -32bps to 0.57% in 2023, then crashed by -88bps to 1.08% in 2024, then rose by 20bps to 0.86% in 2025.
  • Business Quant data shows Return on Sales for CPHI at 0.86% in Q3 2025, 0.52% in Q2 2025, and 0.69% in Q1 2025.